Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

Universita di Verona156 enrolled

Overview

This was a retrospective, observational study. The objective of the study is investigate the efficacy and safety of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Patients were stratified in two groups, those receiving secukinumab at the dose 300 mg every 4 weeks from the beginning (cases) and those who received the initial label, weekly loading dose (controls). Efficacy was evaluated by comparing the proportion of patients achieving PASI75 responses at week 16, 32 and 48 between cases and controls. Safety was evaluated by reporting every adverse events up to week 48.

Study Type

OBSERVATIONAL

Enrollment

156

Conditions

Psoriasis Vulgaris

Interventions

SecukinumabDRUG

Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients older than 18 years old * Patients with moderate to severe chronic plaque psoriasis treated with secukinumab with or without initial loading dose for at least 48 week * The criteria for receiving secukinumab were according to standard clinical practice. Exclusion Criteria: * Patients younger than 18 years old * Patients with only psoriatic arthritis or with other forms of psoriasis than chronic plaque type (such as drug-induced psoriasis or guttate, erythrodermic, or pustular psoriasis) * Pregnant women and women during breastfeeding

Outcomes

Primary Outcomes

PASI75

Time frame: week 48

Secondary Outcomes

PASI90